65 related articles for article (PubMed ID: 38665375)
21. Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Systematic Review and Meta-Analysis of Observational Studies.
Rubín de Célix C; Chaparro M; Gisbert JP
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887966
[TBL] [Abstract][Full Text] [Related]
22. Novel biallelic mutations in the DUOX2 gene underlying very early-onset inflammatory bowel disease: A case report.
Kyodo R; Takeuchi I; Narumi S; Shimizu H; Hata K; Yoshioka T; Tanase-Nakao K; Shimizu T; Arai K
Clin Immunol; 2022 May; 238():109015. PubMed ID: 35429653
[TBL] [Abstract][Full Text] [Related]
23. Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
Rosh JR; Turner D; Griffiths A; Cohen SA; Jacobstein D; Adedokun OJ; Padgett L; Terry NA; O'Brien C; Hyams JS
J Crohns Colitis; 2021 Nov; 15(11):1931-1942. PubMed ID: 34037715
[TBL] [Abstract][Full Text] [Related]
24. Crohn's-like Enteritis in X-Linked Agammaglobulinemia: A Case Series and Systematic Review.
Khan F; Person H; Dekio F; Ogawa M; Ho HE; Dunkin D; Secord E; Cunningham-Rundles C; Ward SC
J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3466-3478. PubMed ID: 34029777
[TBL] [Abstract][Full Text] [Related]
25. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease.
Restellini S; Afif W
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33802816
[TBL] [Abstract][Full Text] [Related]
26. Ustekinumab is effective against small bowel lesions in Crohn's disease: two case reports.
Murate K; Nakamura M; Yamamura T; Maeda K; Sawada T; Mizutani Y; Ishikawa E; Kakushima N; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Fujishiro M
Clin J Gastroenterol; 2021 Feb; 14(1):129-135. PubMed ID: 33118129
[TBL] [Abstract][Full Text] [Related]
27. Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials.
Narula N; Wong ECL; Dulai PS; Marshall JK; Colombel JF; Reinisch W
J Crohns Colitis; 2021 Mar; 15(3):462-470. PubMed ID: 32931556
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study.
Fumery M; Peyrin-Biroulet L; Nancey S; Altwegg R; Gilletta C; Veyrard P; Bouguen G; Viennot S; Poullenot F; Filippi J; Buisson A; Bozon A; Brazier F; Pouillon L; Flourie B; Boivineau L; Siproudhis L; Laharie D; Roblin X; Diouf M; Treton X
J Crohns Colitis; 2020 Sep; ():. PubMed ID: 32898232
[TBL] [Abstract][Full Text] [Related]
29. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.
Takeuchi I; Arai K; Kyodo R; Sato T; Tokita K; Hirano Y; Shimizu H
J Gastroenterol Hepatol; 2021 Jan; 36(1):125-130. PubMed ID: 32497325
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
Ollech JE; Normatov I; Peleg N; Wang J; Patel SA; Rai V; Yi Y; Singer J; Dalal SR; Sakuraba A; Cohen RD; Rubin DT; Pekow J
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):104-110. PubMed ID: 32109634
[TBL] [Abstract][Full Text] [Related]
31. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
[TBL] [Abstract][Full Text] [Related]
32. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
[TBL] [Abstract][Full Text] [Related]
33. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of pediatric-onset Crohn's disease: A population-based cohort study.
Fumery M; Pariente B; Sarter H; Savoye G; Spyckerelle C; Djeddi D; Mouterde O; Bouguen G; Ley D; Peneau A; Dupas JL; Turck D; Gower-Rousseau C;
Dig Liver Dis; 2019 Apr; 51(4):496-502. PubMed ID: 30611597
[TBL] [Abstract][Full Text] [Related]
35. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab to treat Crohn's disease.
Gisbert JP; Chaparro M
Gastroenterol Hepatol; 2017 Dec; 40(10):688-698. PubMed ID: 29042094
[TBL] [Abstract][Full Text] [Related]
39. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
[TBL] [Abstract][Full Text] [Related]
40. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
